FDA approves atezolizumab combination for stage III colon cancer with deficient DNA mismatch repair
The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq) in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).
Read original article on The Medical News →Related news
-
Safety prompts can help AI models make safer clinical choices
United Kingdom
-
Early-onset Alzheimer's disease shows different warning signs from established risk factors
United Kingdom
-
Sloth Bear Named By Julia Roberts is Flourishing After Rescue From Dancing Trade in India
United Kingdom
-
Loneliness may steal nearly 6 years of good health
United States
-
Bowel cancer “melted away” after immunotherapy, then stayed away
United States
-
Why most health apps are biased even before their first lines of code are written
United Kingdom
-
Most labs testing children for cardiac troponin lack pediatric reference ranges, survey finds
United Kingdom
-
The circumstances you grow up in are linked to how long you live
United Kingdom